SURMOUNT-1 Tirzepatide The pivotal tirzepatide trial, published in the New England Journal of Medicine in 2022, randomized 2,539 adults with obesity to tirzepatide 5 mg, 10 mg, 15 mg or placebo for 72 weeks
Which is not a bad thing
Similarly to how you began your GLP-1 protocol by titrating from a conservative dose up to an amount that is uniquely therapeutic for you, you should also gradually ramp up your fiber intake especially if you dont get much or any from your standard diet
After oxidase and 5% bovine serum albumin (BSA) closure, the sections were incubated with anti-TH primary antibody (1:500 dilution, Abcam, UK) at 4 C overnight
Remembering which day to inject is easy
Here are the expected changes in the medications appearance and the therapeutic outcomes